Deals Of The Week: Express Scripts/Walgreens, Par/TPG, Amicus/GSK
Executive Summary
Following the clinical trial failure of cancer candidate saridegib, Infinity takes back partnered assets from Purdue and plans to go it alone in the PI3K space.
You may also be interested in...
Infinity Regains Pipeline Rights, Gives Up Equity In Rejiggered Purdue Alliance
Infinity avoids the erosion of its rights to a promising PI3K drug by restructuring its alliance with Purdue and Mundipharma, essentially returning all control back to the cancer drug developer.
Par Acquisition By TPG Allows Competing Marriage Proposals
Par will be acquired by private equity firm TPG in $1.9 billion deal if no other suitors come forward with a better offer over the next month.
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
The diabetes drug maker has reportedly spurned a buyout offer at a 43% premium, driving up its share price – and perhaps discouraging it from pursuing the partnership it seeks.